News stories about Bruker Corporation (NASDAQ:BRKR) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bruker Corporation earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave news stories about the medical research company an impact score of 47.1986384448651 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:

Shares of Bruker Corporation (BRKR) opened at $32.77 on Wednesday. The stock has a market cap of $5,243.04, a PE ratio of 28.30, a P/E/G ratio of 2.84 and a beta of 1.05. Bruker Corporation has a fifty-two week low of $21.03 and a fifty-two week high of $35.16. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.63 and a quick ratio of 1.61.

Bruker Corporation (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, November 2nd. The medical research company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.02. The firm had revenue of $435.60 million for the quarter, compared to analyst estimates of $415.45 million. Bruker Corporation had a net margin of 8.85% and a return on equity of 25.93%. Bruker Corporation’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.32 EPS. equities analysts predict that Bruker Corporation will post 1.17 earnings per share for the current year.

A number of brokerages have weighed in on BRKR. Bank of America Corporation upgraded Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 price objective on the stock in a report on Friday, November 3rd. BidaskClub lowered Bruker Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Cowen and Company restated a “hold” rating and issued a $29.00 price objective on shares of Bruker Corporation in a report on Friday, November 3rd. Citigroup Inc. raised their price objective on Bruker Corporation from $29.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Finally, J P Morgan Chase & Co upgraded Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 price objective on the stock in a report on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $28.58.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at

In related news, VP Mark Munch sold 21,061 shares of the business’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total value of $631,198.17. Following the sale, the vice president now directly owns 60,524 shares in the company, valued at approximately $1,813,904.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Frank H. Laukien acquired 2,335 shares of Bruker Corporation stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average price of $27.39 per share, for a total transaction of $63,955.65. Following the completion of the acquisition, the chief executive officer now owns 37,791,386 shares in the company, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. 35.20% of the stock is currently owned by insiders.

Bruker Corporation Company Profile

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Insider Buying and Selling by Quarter for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with's FREE daily email newsletter.